TELO
NASDAQTelomir Pharmaceuticals Inc.
News25/Ratings1
News · 26 weeks30+25%
2026-03-012026-08-23
Mix1390d
- SEC Filings6(46%)
- Insider4(31%)
- Other2(15%)
- Market1(8%)
Latest news
25 items- SECSEC Form DEFA14A filed by Telomir Pharmaceuticals Inc.DEFA14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Telomir Pharmaceuticals Inc.SCHEDULE 13G/A - Telomir Pharmaceuticals, Inc. (0001971532) (Subject)
- SECSEC Form 10-Q filed by Telomir Pharmaceuticals Inc.10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- PRTelomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer ModelsMIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of preclinical data of Telomir-Zn suppressing tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The manuscript, titled "Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer," has been published in the Journal of Oncology Research and Therap
- SECSEC Form DEF 14A filed by Telomir Pharmaceuticals Inc.DEF 14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- INSIDERSEC Form 4 filed by Director Macpherson Edward Clouston4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Del Giudice Matthew Paul4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Whalen Matthew Pratt4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes ModelInsulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-i
- INSIDERSEC Form 3 filed by new insider Mushak Andriy3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- INSIDERSEC Form 4 filed by CEO and Chairman Aminov Erez4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Whalen Matthew Pratt4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Macpherson Edward Clouston4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Del Giudice Matthew Paul4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's DiseaseStudy Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model. MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson's disease model, supporti
- SECSEC Form 10-Q filed by Telomir Pharmaceuticals Inc.10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerCompany Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC).This IND clearance enables the Compan
- INSIDERCEO and Chairman Aminov Erez acquired $10,028,003 worth of shares (7,319,710 units at $1.37) (SEC Form 4)4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS Newswire / April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. ("TELI").The transaction, which was approved by Telomir's shareholders at the Company's Annual Meeting held on March 23, 2026, estab
TELO FAQ
6 questionsWhere does TELO stock trade?
Telomir Pharmaceuticals Inc. (TELO) is listed on NASDAQ.What sector and industry is TELO in?
Telomir Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Telomir Pharmaceuticals Inc. go public?
Telomir Pharmaceuticals Inc. (TELO) completed its IPO in 2024.What are analysts saying about TELO?
Telomir Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Rodman & Renshaw: Buy with a $1500.00 price target on 2025-02-21. Recent price targets cluster around $1500.00.What companies are similar to TELO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TELO side-by-side with any of them on Quantisnow.How can I track TELO on Quantisnow?
Quantisnow aggregates Telomir Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TELO to receive live email and push alerts on every new disclosure.